Skip to main
ZBH
ZBH logo

ZBH Stock Forecast & Price Target

ZBH Analyst Ratings

Based on 36 analyst ratings
Buy
Strong Buy 17%
Buy 33%
Hold 42%
Sell 6%
Strong Sell 3%

Bulls say

Zimmer Biomet Holdings is projected to achieve 2025 sales of $7.85 billion and adjusted EPS of $8.23, reflecting growth rates of 4.0% and 2.9%, respectively. The company is anticipated to benefit from operational margin expansion of approximately 30 basis points, aided by its recent spin-out of non-core businesses, which is expected to contribute significantly over time. Positive momentum is noted in the knees and hips segments due to successful new product launches and increased penetration of advanced technologies, indicating a strong position in higher-growth end-markets.

Bears say

The analysis of Zimmer Biomet Holdings indicates a negative outlook primarily due to anticipated revenue growth slowing to 2% or less, driven by weak demand for ROSA robots and disappointing launches of new products. Additionally, projected margin contraction and earnings guidance falling below consensus—$8.25 at the midpoint compared to a consensus of $8.56—further exacerbate concerns regarding financial performance. The firm also faces significant risks, including slower orthopedic market growth, adverse pricing trends, and potential challenges from acquisitions that could dilute earnings.

ZBH has been analyzed by 36 analysts, with a consensus rating of Buy. 17% of analysts recommend a Strong Buy, 33% recommend Buy, 42% suggest Holding, 6% advise Selling, and 3% predict a Strong Sell.

This aggregate rating is based on analysts' research of Zimmer Biomet Hlds and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Zimmer Biomet Hlds (ZBH) Forecast

Analysts have given ZBH a Buy based on their latest research and market trends.

According to 36 analysts, ZBH has a Buy consensus rating as of Jul 10, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $125.81, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $125.81, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Zimmer Biomet Hlds (ZBH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.